A fluorinated analog of ISO-1 blocks the recognition and biological function of MIF and is orally efficacious in a murine model of colitis

European Journal of Pharmacology

Volumn 607, Issue 1-3, 2009, Pages 201-212

  Dagia, Nilesh M ^a   Kamath, Divya V ^a   Bhatt, Pooja ^a   Gupte, Ravindra D ^a   Dadarkar, Shruta S ^a   Fonseca, Lyle ^a   Agarwal, Gautam ^a   Chetrapal Kunwar, Anshu ^a   Balachandran, Sarala ^a   Srinivasan, Shaila ^a   Bose, Julie ^a   Pari, Koteppa ^a   B Rao, Chandrika ^a   Parkale, Santosh S ^a   Gadekar, Pradip K ^a   Rodge, Atish H ^a   Mandrekar, Noopur ^a   Vishwakarma, Ram A ^a   Sharma, Somesh ^a  

^a Piramal Enterprises Limited   (India)

Author keywords

Colon; Cytokine; Dopachrome; Inflammation; ISO 1; MIF

Indexed keywords

4 [4 (FURAN 2 CARBONYL)PIPERAZIN 1 YL] 1 METHYL 3 NITROQUINOLIN 2(1H) ONE; DEXTRAN SULFATE; DOPACHROME; HEMOGLOBIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOXAZOLE DERIVATIVE; MACROPHAGE MIGRATION INHIBITION FACTOR; NEOPENTYL 2 [3 (3 FLUORO 4 HYDROXYPHENYL) 4,5 DIHYDROISOXAZOL 5 YL]ACETATE; PROTEIN INHIBITOR; QUINOLINE DERIVATIVE; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CATALYSIS; CIRCULAR DICHROISM; COLITIS; COLON HEMORRHAGE; COLON MUCOSA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; EDEMA; EMBRYO; FECES ANALYSIS; FISH; FLUORINATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IC 50; IMMUNOREGULATION; INFLAMMATORY INFILTRATE; INTESTINE CRYPT; MOLECULAR DOCKING; MOLECULAR RECOGNITION; MORPHOMETRICS; MORTALITY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTECTION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RECTUM HEMORRHAGE; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; ISOXAZOLES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; MICE, INBRED C57BL; MONOCYTES; QUINOLINES;

EID: 62149130434     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.02.031     Document Type: Article

References (39)

1. Al-Abed Y., Dabideen D., Aljabari B., Valster A., Messmer D., Ochani M., Tanovic M., Ochani K., Bacher M., Nicoletti F., Metz C., Pavlov V.A., Miller E.J., and Tracey K.J. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J. Biol. Chem. 280 (2005) 36541-36544
2. Baugh J.A., and Bucala R. Macrophage migration inhibitory factor. Crit. Care Med. 30 (2002) S27-35
3. Bernhagen J., Krohn R., Lue H., Gregory J.L., Zernecke A., Koenen R.R., Dewor M., Georgiev I., Schober A., Leng L., Kooistra T., Fingerle-Rowson G., Ghezzi P., Kleemann R., McColl S.R., Bucala R., Hickey M.J., and Weber C. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 13 (2007) 587-596
4. Beswick E.J., and Reyes V.E. MIF and IL-8 produced by gastric epithelial cells during Helicobater pylori exposure induce EGFR expression and activation. Infect. Immun. 76 (2008) 3233-3240
5. Bhonde M.R., Gupte R.D., Dadarkar S.D., Jadhav M.G., Tannu A.A., Bhatt P., Bhatia D.R., Desai N.K., Deore V., Yewalkar N., Vishwakarma R.A., Sharma S., Kumar S., and Dagia N.M. A novel mTOR inhibitor is efficacious in a murine model of colitis. Am. J. Physiol. Gastrointest. Liver. Physiol. 295 (2008) G1237-1245
6. Burger-Kentischer A., Goebel H., Seiler R., Fraedrich G., Schaefer H.E., Dimmeler S., Kleemann R., Bernhagen J., and Ihling C. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation. 105 (2002) 1561-1566
7. Cheng K.F., and Al-Abed Y. Critical modifications of the ISO-1 scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg. Med. Chem. Lett. 16 (2006) 3376-3379
8. Crichlow G.V., Cheng K.F., Dabideen D., Ochani M., Aljabari B., Pavlov V.A., Miller E.J., Lolis E., and Al-Abed Y. Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor. J. Biol. Chem. 282 (2007) 23089-23095
9. Cvetkovic I., Al-Abed Y., Miljkovic D., Maksimovic-Ivanic D., Roth J., Bacher M., Lan H.Y., Nicoletti F., and Stosic-Grujicic S. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology. 146 (2005) 2942-2951
10. Dabideen D.R., Cheng K.F., Aljabari B., Miller E.J., Pavlov V.A., and Al-Abed Y. Phenolic hydrazones are potent inhibitors of macrophage migration inhibitory factor proinflammatory activity and survival improving agents in sepsis. J. Med. Chem. 50 (2007) 1993-1997
11. Dagia N.M., Harii N., Meli A.E., Sun X., Lewis C.J., Kohn L.D., and Goetz D.J. Phenyl methimazole inhibits TNF-alpha-induced VCAM-1 expression in an IFN regulatory factor-1-dependent manner and reduces monocytic cell adhesion to endothelial cells. J. Immunol. 173 (2004) 2041-2049
12. Dagia N.M., Gadhoum S.Z., Knoblauch C.A., Spencer J.A., Zamiri P., Lin C.P., and Sackstein R. G-CSF induces E-selectin ligand expression on human myeloid cells. Nat. Med. 12 (2006) 1185-1190
13. de Jong Y.P., Abadia-Molina A.C., Satoskar A.R., Clarke K., Rietdijk S.T., Faubion W.A., Mizoguchi E., Metz C.N., Alsahli M., ten Hove T., Keates A.C., Lubetsky J.B., Farrell R.J., Michetti P., van Deventer S.J., Lolis E., David J.R., Bhan A.K., and Terhorst C. Development of chronic colitis is dependent on the cytokine MIF. Nat. Immunol. 2 (2001) 1061-1066
14. Dios A., Mitchell R.A., Aljabari B., Lubetsky J., O'Connor K., Liao H., Senter P.D., Manogue K.R., Lolis E., Metz C., Bucala R., Callaway D.J., and Al-Abed Y. Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J. Med. Chem. 45 (2002) 2410-2416
15. Fantini M.C., and Pallone F. Cytokines: from gut inflammation to colorectal cancer. Curr. Drug Targets. 9 (2008) 375-380
16. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 115 (1998) 182-205
17. Flieger O., Engling A., Bucala R., Lue H., Nickel W., and Bernhagen J. Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett. 551 (2003) 78-86
18. Gaeta, F.C.A., Baird, A., Anchin, J., Ying, W., Florkiewicz, R., Sircar, J., Sunilkumar, K.C., 2006, Inhibitors of macrophage migration inhibitory factor and methods for identifying the same (Avanir Pharmaceuticals, USA US7,129,236B2).
19. Hoi A.Y., Iskander M.N., and Morand E.F. Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. Inflamm. Allergy Drug Targets. 6 (2007) 183-190
20. Leech M., Metz C., Santos L., Peng T., Holdsworth S.R., Bucala R., and Morand E.F. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum. 41 (1998) 910-917
21. Lubetsky J.B., Dios A., Han J., Aljabari B., Ruzsicska B., Mitchell R., Lolis E., and Al-Abed Y. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem. 277 (2002) 24976-24982
22. Meyer-Siegler K.L., Iczkowski K.A., Leng L., Bucala R., and Vera P.L. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J. Immunol. 177 (2006) 8730-8739
23. Mitchell R.A., and Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin. Cancer Biol. 10 (2000) 359-366
24. Morand E.F., Leech M., Weedon H., Metz C., Bucala R., and Smith M.D. Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. Rheumatology (Oxford). 41 (2002) 558-562
25. Morand E.F., Leech M., and Bernhagen J. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat. Rev. Drug Discov. 5 (2006) 399-410
26. Nagel R. DarT: the embryo test with the zebrafish Danio rerio-a general model in ecotoxicology and toxicology. Altex 19 Suppl 1 (2002) 38-48
27. Ohkawara T., Nishihira J., Takeda H., Hige S., Kato M., Sugiyama T., Iwanaga T., Nakamura H., Mizue Y., and Asaka M. Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology 123 (2002) 256-270
28. Ohkawara T., Nishihira J., Ishiguro Y., Otsubo E., Nagai K., Takeda H., Kato M., Yoshiki T., Iwanaga T., and Asaka M. Resistance to experimental colitis depends on cytoprotective heat shock proteins in macrophage migration inhibitory factor null mice. Immunol. Lett. 107 (2006) 148-154
29. Ohkawara T., Mitsuyama K., Takeda H., Asaka M., Fujiyama Y., and Nishihira J. Lack of macrophage migration inhibitory factor suppresses innate immune response in murine dextran sulfate sodium-induced colitis. Scand. J. Gastroenterol. 43 (2008) 1497-1504
30. Onodera S., Nishihira J., Koyama Y., Majima T., Aoki Y., Ichiyama H., Ishibashi T., and Minami A. Macrophage migration inhibitory factor up-regulates the expression of interleukin-8 messenger RNA in synovial fibroblasts of rheumatoid arthritis patients: common transcriptional regulatory mechanism between interleukin-8 and interleukin-1beta. Arthritis Rheum. 50 (2004) 1437-1447
31. Orita M., Yamamoto S., Katayama N., Aoki M., Takayama K., Yamagiwa Y., Seki N., Suzuki H., Kurihara H., Sakashita H., Takeuchi M., Fujita S., Yamada T., and Tanaka A. Coumarin and chromen-4-one analogues as tautomerase inhibitors of macrophage migration inhibitory factor: discovery and X-ray crystallography. J. Med. Chem. 44 (2001) 540-547
32. Pan J.H., Sukhova G.K., Yang J.T., Wang B., Xie T., Fu H., Zhang Y., Satoskar A.R., David J.R., Metz C.N., Bucala R., Fang K., Simon D.I., Chapman H.A., Libby P., and Shi G.P. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 109 (2004) 3149-3153
33. Pari K., Sundari C.S., Chandani S., and Balasubramanian D. Beta-carbolines that accumulate in human tissues may serve a protective role against oxidative stress. J. Biol. Chem. 275 (2000) 2455-2462
34. Senter P.D., Al-Abed Y., Metz C.N., Benigni F., Mitchell R.A., Chesney J., Han J., Gartner C.G., Nelson S.D., Todaro G.J., and Bucala R. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 144-149
35. Sun H.W., Bernhagen J., Bucala R., and Lolis E. Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 5191-5196
36. Verdonk M.L., Cole J.C., Hartshorn M.J., Murray C.W., and Taylor R.D. Improved protein-ligand docking using GOLD. Proteins 52 (2003) 609-623
37. Wang L., Das H., Kamath A., Li L., and Bukowski J.F. Human V gamma 2V delta 2 T cells augment migration-inhibitory factor secretion and counteract the inhibitory effect of glucocorticoids on IL-1 beta and TNF-alpha production. J. Immunol. 168 (2002) 4889-4896
38. West P.W., Parker L.C., Ward J.R., and Sabroe I. Differential and cell-type specific regulation of responses to Toll-like receptor agonists by ISO-1. Immunology 125 (2008) 101-110
39. Wilson J.M., Coletta P.L., Cuthbert R.J., Scott N., MacLennan K., Hawcroft G., Leng L., Lubetsky J.B., Jin K.K., Lolis E., Medina F., Brieva J.A., Poulsom R., Markham A.F., Bucala R., and Hull M.A. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 129 (2005) 1485-1503